Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year's San Antonio Breast Cancer meeting. I'm Hope Rugo, professor of medicine at the University of California San Francisco's Comprehensive Cancer Center, and I'm joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco's Comprehensive Cancer Center. Thanks for joining me today.
Now I think what we'll do is focus on novel therapy, some of the novel therapies that were presented at San Antonio. We can't be exhaustive, of course, but we'll talk about some of the agents that either are already being used in the clinic or are emerging agents. One area of great interest is oral taxanes. We've been trying to get oral taxanes for ages. There is a problem with absorption due to P-glycoprotein and also problems just with the formulations of these agents. But we saw data from one really interesting trial presented for the first time, the CONTESSA trial, looking at tesetaxel, a novel taxane, and capecitabine combined in hormone receptor-positive metastatic disease.